Bringing back targets to "IMPROVE" atherosclerotic cardiovascular disease outcomes: the duel for dual goals; are two targets better than one?
From Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins University School of Medicine, Baltimore, MD.
Erin D
ED
Michos
From Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins University School of Medicine, Baltimore, MD.
Seth S
SS
Martin
From Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins University School of Medicine, Baltimore, MD. rblument1@jhmi.edu.
Roger S
RS
Blumenthal
D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000032:analysis*; D008078:Cholesterol, LDL / Q000097:blood*; D000069438:Ezetimibe / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D019821:Simvastatin / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D002097:C-Reactive Protein; D019821:Simvastatin; D000069438:Ezetimibe
Editorials; inflammation; lipids; risk assessment